Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giampaolo Tortora
Observed name:
Tortora Giampaolo
Institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
Observed institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
ORCID:
0000-0002-1378-4962
Observed ORCID:
0000-0002-1378-4962
OpenAlex ID:
A5130630722
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
2023
·
Robin Kate Kelley
, Makoto Ueno
, et al.
·
The Lancet
·
1,375
Evolutionary fingerprints of epithelial-to-mesenchymal transition
2025
·
Luigi Perelli
, Li Zhang
, et al.
·
Nature
·
55
PDF
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial
2024
·
D. Ciardiello
, L. Boscolo Bielo
, et al.
·
Annals of Oncology
·
33
PDF
Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis
2025
·
Federico Monaca
, Igor Gomez-Randulfe
, et al.
·
European Journal of Cancer
·
13
PDF
Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy
2025
·
Federico Monaca
, Igor Gomez-Randulfe
, et al.
·
European Journal of Cancer
·
13
PDF
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study
2025
·
Davide Ciardiello
, Luca Boscolo Bielo
, et al.
·
European Journal of Cancer
·
11
Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
2026
·
Mariano Ponz-Sarvisé
, Sun Young Rha
, et al.
·
Cancer Research Communications
·
10
PDF
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients.
2024
·
Giulia Orsi
, Catia Carconi
, et al.
·
European Journal of Cancer
·
9
Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer
2026
·
Camilla Nero
, Lisa Salvatore
, et al.
·
Targeted Oncology
·
4
PDF
Predicting progression-free survival in hormone-receptor positive (HR+/HER2–) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors: A machine learning approach
2026
·
Sergio Pannunzio
, Luca Mastrantoni
, et al.
·
The Breast
·
4
PDF
Adjuvant chemotherapy with cisplatin and gemcitabine compared with standard of care after curative intent resection of cholangiocarcinoma and muscle-invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial)
2026
·
A. Stein
, J. Bridgewater
, et al.
·
Annals of Oncology
·
2
PDF
Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors
2026
·
Ilaria Poli
, Gaia Rachele Oliva
, et al.
·
Journal of Personalized Medicine
·
2
PDF
Complete Response to Lorlatinib in Lung Adenocarcinoma With EML4-ALK Fusion Variant (E6;A18): Case Report and Literature Review
2025
·
Antonio Vitale
, Elisa De Paolis
, et al.
·
Journal of the National Comprehensive Cancer Network
·
2
Germline pathogenic variants identification through comprehensive cancer genome profiling
2026
·
Simona Duranti
, Arianna Panfili
, et al.
·
Genome Medicine
Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial
2026
·
Makoto Ueno
, Changhoon Yoo
, et al.
·
EClinicalMedicine
Figure 1 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
2026
·
Mariano Ponz-Sarvisé
, Sun Young Rha
, et al.
Supplementary Figure 1 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
2026
·
Mariano Ponz-Sarvisé
, Sun Young Rha
, et al.
Figure 2 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
2026
·
Mariano Ponz-Sarvisé
, Sun Young Rha
, et al.
Supplementary Figure 10 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
2026
·
Mariano Ponz-Sarvisé
, Sun Young Rha
, et al.
Data Availability Statement from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
2026
·
Mariano Ponz-Sarvisé
, Sun Young Rha
, et al.
Figure 4 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
2026
·
Mariano Ponz-Sarvisé
, Sun Young Rha
, et al.
Supplementary Figure 6 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
2026
·
Mariano Ponz-Sarvisé
, Sun Young Rha
, et al.
Supplementary Figure 5 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
2026
·
Mariano Ponz-Sarvisé
, Sun Young Rha
, et al.
Supplementary Figure 9 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
2026
·
Mariano Ponz-Sarvisé
, Sun Young Rha
, et al.
Supplementary Table 5 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
2026
·
Mariano Ponz-Sarvisé
, Sun Young Rha
, et al.
Show more works
View as search
Works count:
50
Citation count:
1,533
H-index:
8
I10-index:
7
Year
Topic
Type